MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.55
+0.31
+1.33%
After Hours: 23.69 +0.14 +0.59% 16:07 09/27 EDT
OPEN
23.36
PREV CLOSE
23.24
HIGH
23.79
LOW
22.95
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
24.18
52 WEEK LOW
9.72
MARKET CAP
3.02B
P/E (TTM)
-18.9066
1D
5D
1M
3M
1Y
5Y
Aurinia Pharmaceuticals Inc (AUPH) EVP of Research Robert Bindert Huizinga Sold $779,675 of Shares
GuruFocus News · 4d ago
Insider Sell: Aurinia Pharmaceuticals
MT Newswires · 5d ago
Implied Volatility Surging for Aurinia (AUPH) Stock Options
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Zacks · 09/20 13:02
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the senior management team will present at the following upcoming virtual investor conferences:
Business Wire · 09/15 17:11
Notable Aurinia Pharmaceuticals Insider Trades $2.92 Million In Company Stock
Michael Robert Martin, Chief Business Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), made a large buy and sell of company shares on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commiss...
Benzinga · 09/15 14:40
Aurinia Pharmaceuticals Inc (AUPH) EVP of Research Robert Bindert Huizinga Sold $687,375 of Shares
GuruFocus News · 09/14 12:40
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation w...
Business Wire · 09/10 17:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AUPH. Analyze the recent business situations of Aurinia Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AUPH stock price target is 28.33 with a high estimate of 35.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 201
Institutional Holdings: 53.56M
% Owned: 41.80%
Shares Outstanding: 128.16M
TypeInstitutionsShares
Increased
58
6.54M
New
29
1.19M
Decreased
40
5.67M
Sold Out
32
5.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.22%
Pharmaceuticals & Medical Research
-0.92%
Key Executives
Chairman/Independent Director
George Milne
President/Chief Executive Officer/Director
Peter Greenleaf
Chief Financial Officer
Joe Miller
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Stephen Robertson
Executive Vice President
Matthew Donley
Executive Vice President
Robert Huizinga
Senior Vice President/IR Contact Officer
Glenn Schulman
Chief Marketing Officer
Neil Solomons
Other
Massimiliano Colao
Other
Michael Martin
Director
Brinda Balakrishnan
Director
Daniel Billen
Director
R. Hector MacKay-Dunn
Independent Director
Joseph Hagan
Independent Director
David Jayne
Independent Director
Jill Leversage
Independent Director
Timothy Walbert
No Data
About AUPH
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.